Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries

Benzarti, S.; Daskalakis, Michael; Feller, Anita; Bacher, Vera Ulrike; Schnegg-Kaufmann, Annatina; Rüfer, Axel; Holbro, Andreas; Schmidt, Adrian; Benz, Rudolf; Solenthaler, Max; Stüssi, Georg; Arndt, Volker; Bonadies, Nicolas

doi:10.1016/j.canep.2019.01.003

Cited by 14 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival ranges from months to decades, with a median of around 13 months 1,2 . The 5‐year cumulative progression to acute myeloid leukaemia (AML) is reported to be 21–29% 8,9 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study

et al. 2020

View full text Add to dashboard Cite

Summary Outcomes in chronic myelomonocytic leukaemia (CMML) are highly variable and may be affected by comorbidity. Therefore, prognostic models and comorbidity indices are important tools to estimate survival and to guide clinicians in individualising treatment. In this nationwide population‐based study, we assess comorbidities and for the first time validate comorbidity indices in CMML. We also compare the prognostic power of: the revised International Prognostic Scoring System (IPSS‐R), CMML‐specific prognostic scoring system (CPSS), MD Anderson Prognostic Scoring System (MDAPS) and Mayo score. In this cohort of 337 patients with CMML, diagnosed between 2009 and 2015, the median overall survival was 21·3 months. Autoimmune conditions were present in 25% of the patients, with polymyalgia rheumatica and Hashimoto’s thyroiditis being most common. Of the tested comorbidity indices: the Charlson Comorbidity Index (CCI), Haematopoietic cell transplantation‐specific Comorbidity Index (HCT‐CI) and Myelodysplastic Syndrome‐Specific Comorbidity Index (MDS‐CI), CCI had the highest C‐index (0·62) and was the only comorbidity index independently associated with survival in multivariable analyses. When comparing the prognostic power of the scoring systems, the CPSS had the highest C‐index (0·69). In conclusion, using ‘real‐world’ data we found that the CCI and CPSS have the best prognostic power and that autoimmune conditions are overrepresented in CMML.

show abstract

“…Survival ranges from months to decades, with a median of around 13 months 1,2 . The 5‐year cumulative progression to acute myeloid leukaemia (AML) is reported to be 21–29% 8,9 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In children with JMML the 5-year survival rate was 56% for males and 66% for females, without treatment data given. -------------------------------~0.3-0.4 (31,33,34,62); 1 (36); 4.1 (32) cases per 100 000;…”

Section: Epidemiology Of Mds/mpnmentioning

confidence: 99%

“…In a comparative study between Switzerland and the US (SEER-data) Benzarti et al described epidemiological trends regarding CMML between 1999 and 2014 (33). The age standardized incidence was similar and remained relatively stable in both countries, being 0.32 (1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006) and 0.38 (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014) in Switzerland and 0.37 and 0.35 in the US.…”

Section: Epidemiology Of Mds/mpnmentioning

confidence: 99%

“…CMML is by far the most frequent of MDS/MPNs. Published incidence rates range from 0.3-4.1 per 100 000 inhabitants with a median age above 70 years and a male predominance (31)(32)(33)(34)(35)(36)63). CMML might be described as even more heterogeneous when compared to MDS, with hematological characteristics ranging from solely dysplastic forms, presenting often cytopenic and resembling MDS with peripheral monocytosis to very proliferative forms, characterized by high white blood cell counts, but also by splenomegaly, extramedullary involvement, and strong general symptoms.…”

Section: Epidemiology Of Mds/mpnmentioning

confidence: 99%

See 1 more Smart Citation

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

2021

View full text Add to dashboard Cite

The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms. The group consists of chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, BCR-ABL1-negative (aCML), juvenile myelomonocytic leukemia (JMML), myelodysplastic/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). The most frequent entity in this category is CMML, while all other diseases are extremely rare. Thus, only very limited data on the epidemiology of these subgroups exists. An appropriate diagnosis and classification can be challenging since the diagnosis is still largely based on morphologic criteria and myelodysplastic as well as myeloproliferative features can be found in various occurrences. The diseases in this category share several features that are common in this specific WHO-category, but also exhibit specific traits for each disease. This review summarizes published data on epidemiological features and offers a brief overview of the main diagnostic criteria and clinical characteristics of the five MDS/MPN subgroups.

show abstract

“…CMML is a clonal neoplastic hematopoietic stem cell disorder, characterized by dysplasia, monocytosis, and increased risk of transformation to sAML [ 1 ]. According to several population-based studies, about 0.3–0.7 new cases per 100,000 people are reported each year in both the United States and European countries [ 2 , 3 , 4 , 5 ]. The incidence was shown to be influenced by age, gender, and race, with higher frequency of CMML in old white males [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Mouse Models of CMML

Belotserkovskaya

Demidov

2021

IJMS

View full text Add to dashboard Cite

Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortality, associated predominantly with progression to secondary acute myeloid leukemia (sAML), is still an unsolved problem. Despite a growing body of knowledge about the molecular repertoire of this disease, at present, the prognostic significance of CMML-associated mutations is controversial. The absence of available CMML cell lines and the small number of patients with CMML make pre-clinical testing and clinical trials complicated. Currently, specific therapy for CMML has not been approved; most of the currently available therapeutic approaches are based on myelodysplastic syndrome (MDS) and other myeloproliferative neoplasm (MNP) studies. In this regard, the development of the robust CMML animal models is currently the focus of interest. This review describes important studies concerning animal models of CMML, examples of methodological approaches, and the obtained hematologic phenotypes.

show abstract

Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries

Cited by 14 publications

References 29 publications

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Mouse Models of CMML

Contact Info

Product

Resources

About